LIVING WITH CRC
Lean Body Mass Linked to Oxaliplatin Neuropathy RiskA study of colorectal cancer patients receiving adjuvant CAPOX found that lean body mass and sarcopenia may influence the risk of dose-limiting peripheral neuropathy, suggesting current body-surface-area dosing may not account for important individual differences. (Cancer Treatment and Research Communications)